Assisting in the diagnosis of arterial or venous prethrombotic states in various pathological and clinical situations including disseminated intravascular coagulation (DIC) and postoperative monitoring of surgeries with a high risk of thromboses
Only orderable as part of a coagulation reflex. For more information see:
ALUPP / Lupus Anticoagulant Profile, Plasma
ALBLD / Bleeding Diathesis Profile, Limited, Plasma
AATHR / Thrombophilia Profile, Plasma
APROL / Prolonged Clot Time Profile, Plasma
ADIC / Disseminated Intravascular Coagulation/Intravascular Coagulation and Fibrinolysis (DIC/ICF) Profile, Plasma
Latex Immunoassay (LIA)
Plasma Na Cit
Only orderable as part of a coagulation reflex. For more information see:
ALUPP / Lupus Anticoagulant Profile, Plasma
ALBLD / Bleeding Diathesis Profile, Limited, Plasma
AATHR / Thrombophilia Profile, Plasma
APROL / Prolonged Clot Time Profile, Plasma
ADIC / Disseminated Intravascular Coagulation/Intravascular Coagulation and Fibrinolysis (DIC/ICF) Profile, Plasma
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Frozen | 14 days |
Assisting in the diagnosis of arterial or venous prethrombotic states in various pathological and clinical situations including disseminated intravascular coagulation (DIC) and postoperative monitoring of surgeries with a high risk of thromboses
Fibrin monomers are intermediate products formed during the proteolysis of fibrinogen by thrombin. During intravascular coagulation, low levels of thrombin are available in the blood, but the quantity of fibrin monomers formed are not sufficient to aggregate and form a clot; instead, they associate themselves with fibrinogen or fibrinogen-degradation products to form soluble complexes (ie, soluble fibrin monomer complex: SFMC). Intravascular coagulation and fibrinolysis (ICF) or disseminated intravascular coagulation: DIC is a clinical diagnosis; no single test is completely sensitive or specific for ICF.
Only orderable as part of a coagulation reflex. For more information see:
ALUPP / Lupus Anticoagulant Profile, Plasma
ALBLD / Bleeding Diathesis Profile, Limited, Plasma
AATHR / Thrombophilia Profile, Plasma
APROL / Prolonged Clot Time Profile, Plasma
ADIC / Disseminated Intravascular Coagulation/Intravascular Coagulation and Fibrinolysis (DIC/ICF) Profile, Plasma
< or =8 mcg/mL
A normal soluble fibrin monomer complex (SFMC) does not exclude the presence of thrombosis or early disseminated intravascular coagulation (DIC)/intravascular coagulation and fibrinolysis (ICF). An elevated SFMC may be seen in patients with venous or arterial thromboembolism or DIC/ICF. It may also be mildly elevated in clotted specimens.
Lipemia can interfere with this assay, causing an underestimation of the soluble fibrin monomer complex (SFMC) level. Therefore, results from lipemic specimens should be interpreted with caution.
1. Dempfle CE: The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state Thrombosis and Haemostasis 1999;82:673
2. Wada H: Increased plasma soluble fibrin monomer levels in patients with disseminated intravascular coagulation American Journal of Hematology 1996;51:255
3. Leko M: Soluble fibrin monomer degradation products as a potential useful marker for hypercoagulable states with accelerated fibrinolysis. Clinica Chimica Acta 2007;386:38
This assay is based on the change in turbidity of a microparticle suspension that is measured by photometry. A suspension of latex microparticles, coated by covalent bonding with monoclonal antibodies specific for fibrin monomers, is mixed with the plasma to be assayed. An antigen-antibody reaction takes place, leading to an agglutination of the latex microparticles, which induces an increase in turbidity of the reaction medium. This increase in turbidity is reflected by an increase in absorbance, the latter being measured photometrically. The increase in absorbance is a function of the soluble fibrin monomer complex (SFMC) level present in the test sample.(Package insert: STA-Liatest FM Package Insert. Diagnostica Stago, Inc, December 2009)
Monday through Friday
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
85366
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
SOLFM | Soluble Fibrin Monomer | 93748-2 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
SOLFM | Soluble Fibrin Monomer | 93748-2 |